SCHEMBL1009626

SCHEMBL1009626

CN(c1ccccc1)c1cn[nH]c(=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.45
PTGS1 P23219 1/20 0.42
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
GAA P10253 1/20 0.41
DHFR P00374 1/20 0.41
GSK3B P49841 1/20 0.40
HSD17B10 Q99714 1/20 0.39
HPGD P15428 2/20 0.39
NR3C2 P08235 1/20 0.39
KDR P35968 1/20 0.38
PTPN1 P18031 1/20 0.38
CES1 P23141 1/20 0.38
KDM4C Q9H3R0 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
EGFR P00533 1/20 0.37
SRC P12931 1/20 0.37
CYP1A2 P05177 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21590967 0.80 ALDH1A1 (0.37) PTGS1PRMT5WDR77HSD17B10MEN1
SCHEMBL22467859 0.77 MAPT (0.42) PTGS1GAAHPGDL3MBTL1MEN1
SCHEMBL19873384 0.77 MAPT (0.42) PTGS1GAAHPGDL3MBTL1MEN1
SCHEMBL3259672 0.73 AKT1 (0.45) CSF1RDHFRGSK3BNR3C2KDM4C
SCHEMBL20385081 0.72 MEN1 (0.52) GSK3BHPGDNR3C2PTPN1CES1
SCHEMBL22931682 0.72 MEN1 (0.52) GSK3BHPGDNR3C2PTPN1CES1
SCHEMBL31886 0.72 MEN1 (0.52) GSK3BHPGDNR3C2PTPN1CES1
Benzene SCHEMBL14537401 0.72 MEN1 (0.52) GSK3BHPGDNR3C2PTPN1CES1
SCHEMBL6567354 0.72 MEN1 (0.52) GSK3BHPGDNR3C2PTPN1CES1
SCHEMBL1008528 0.71 PKM (0.43) CSF1RGSK3BHSD17B10EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102007116-B Pyridazinone glucokinase activators HOFFMAN-LA ROCHE LTD. (CH) 2014-10-22 CN disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
CN-102007116-A Pyridazinone glucokinase activators HOFFMANN LA ROCHE 2011-04-06 CN disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK CSF1R 3964/4885PTGS1 1685/4885PRMT5 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.